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Summary
Early-onset acromegaly causing gigantism is often associated with aryl-hydrocarbon-interacting receptor protein (AIP) 
mutation, especially if there is a positive family history. A15y male presented with tiredness and visual problems. He was 
201 cm tall with a span of 217 cm. He had typical facial features of acromegaly, elevated IGF-1, secondary hypogonadism 
and a large macroadenoma. His paternal aunt had a history of acromegaly presenting at the age of 35 years. Following 
transsphenoidal surgery, his IGF-1 normalized and clinical symptoms improved. He was found to have a novel AIP 
mutation destroying the stop codon c.991T>C; p.*331R. Unexpectedly, his father and paternal aunt were negative for this 
mutation while his mother and older sister were unaffected carriers, suggesting that his aunt represents a phenocopy.
Background
Early-onset acromegaly causing gigantism is associated 
with mutations in the aryl-hydrocarbon-interacting 
receptor protein (AIP) gene in 30–40% of the cases (1, 2), 
but chances are even higher if there is a positive family 
history of acromegaly. Here, we present a case with typical 
clinical features with a novel AIP mutation but unexpected 
genetic testing results in the family.
Case presentation
A 15-year-old male was referred to the endocrinology clinic 
for excessive fatigue and sleepiness. He was born through 
normal vaginal delivery and his birth weight was 3.5 kg. He 
grew normally until he was 11, after which he experienced 
an accelerated height velocity and increase in weight. 
He developed voice change around the age of 12 years 
and began growing pubic hair when he was 13 years. He 
developed left hip pain when he was 14 and was found to 
have mild scoliosis and his right leg was 2.5 cm shorter than 
the left. He noticed tingling of both hands and gradual loss 
of vision over 6 months, which rapidly deteriorated about 
2 weeks prior to his presentation. His mother mentioned 
that he snored heavily during sleep and slept on a semi-
reclined couch because he was unable to lay flat.
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Learning points:
 • Typical presentation for a patient with AIP mutation with excess growth and eunuchoid proportions.
 • Unusual, previously not described AIP variant with loss of the stop codon.
 • Phenocopy may occur in families with a disease-causing germline mutation.
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His father was First Nation’s descent and mother was 
Caucasian. Mid-parental height was 179.2 cm (50th–75th 
percentile). His parents and older sister had normal 
height and no medical concerns. His paternal aunt had 
undergone surgery for a growth hormone-producing 
adenoma at the age of 35 years.
On examination, his height was 201.2 cm and weight 
was 126.2 kg (BMI = 31.3 kg/m2) (Fig.  1A). His shoe size 
was American 16 EEE (extra-wide). His sitting height was 
100 cm, arm span was 217 cm and bone age was between 
14.5 and 15 years. He had evidence of scoliosis. Goldmann 
visual fields showed bilateral hemianopia (Fig.  1B). His 
skin was pale and greasy, facial features were coarse with 
significant prognathism and widely spaced teeth. Tinel’s 
sign was negative.
Investigation
Goldmann visual field tests revealed bilateral hemianopia 
(Fig.  1B). His baselines endocrine investigations 
showed a 09:00 h cortisol of 98 nmol/L ((normal range 
(NR) = 145–612), TSH: 2.37 IU/L (NR = 0.35–5.4), 
fT4: 8.8 pmol/L (NR = 11–19), prolactin: 15.4 µg/L 
(NR = 2.1–17.7), random GH: 13.4 µg/L (NR < 3.0), 
IGF-1: 1600 µg/L (NR = 232–1077 for his age and sex), 
testosterone <0.3 nmol/L (NR = 8.0–32), FSH: 0.5 IU/L 
(NR = 1.5–9.3), LH: 0.4 IU/L (NR = 1.4–18.1), total calcium: 
2.31 mmol/L (NR = 2.23–2.58) and nadir GH after 75 g oral 
glucose tolerance test of 7.9 µg/L. His MRI scan showed 
a 4.0 × 3.3 × 2.8 cm pituitary macroadenoma with bilateral 
cavernous sinus and suprasellar extension, which was 
hyperintense on T2 weighted images (Fig. 1C). The X-ray 
of the hips did not show any radiological evidence of 
slipped femoral epiphyses or avascular necrosis.
Treatment
A diagnosis of gigantism with eunuchoid proportions 
and associated hypopituitarism was made on the basis of 
typical clinical features, elevated serum IGF-1 and non-
suppressed GH after oral glucose. Pituitary replacement 
therapy was initiated with oral hydrocortisone, thyroxine 
and long-acting injectable testosterone. He underwent 
transsphenoidal excision of the pituitary tumor and the 
pathology confirmed a sparsely granulated eosinophilic 
somatotroph adenoma (Fig. 2) with a Ki-67 index of 5% 
and positive immunostaining for GH as well as scattered 
staining for prolactin and TSH. SSTR2 and SSTR5 staining 
did not show characteristic membranous staining. 
AIP staining showed faint positivity. Surgery led to 
normalization of GH and IGF-1 with post-OGTT GH of 
0.2 µg/L and IGF-1 of 302 µg/L. Post-surgery MRI is shown 
in Fig. 1D.
Outcome and follow-up
His visual fields normalized with complete restoration of 
vision after surgery (Fig. 1C) and the tingling of his hands 
Figure 1
(A) Patient 5 years after surgery; Goldmann visual field test before (B) and after (C) surgery; MRI images of the adenoma before (D) and after surgery (E).
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also improved. He remains in remission 5 years after surgery 
with serum IGF-1 of 225 µg/L (NR = 147–283) and fasting 
GH of 0.26 µg/L as well as pituitary replacement therapy. 
Based on the family history, invasive macroadenoma, 
male gender and young age at presentation, he was 
offered genetic testing. The test identified an aryl-
hydrocarbon-interacting receptor protein (AIP) variant 
c.991T>C; p.*331R (Fig. 3), which has not been previously 
described. Sequencing of the AIP gene in the tumor DNA 
suggest the presence of loss of heterozygosity (Fig.  3C 
and D), although some normal tissue was present in 
the sample. Subsequent family screening showed the 
same variant in her mother and sister (Fig. 3A); physical 
examination and radiological or biochemical assessments 
showed no abnormalities. Siblings of the patient’s mother 
were invited for genetic testing. The proband’s father was 
negative for the mutation. We also tested a paraffin block 
available from his paternal aunt and no mutation was 
detected, suggesting that her case was a phenocopy.
Discussion
This patient had a typical clinical course of an AIP 
mutation-related pituitary adenoma with early-onset 
Figure 2
Haematoxylin & eosin (H&E), reticulin, GH, cytokeratin 8–18 staining, AIP (Novus, 1:1000), SSTR2 (Abcam, 1:500) and SSTR5 (Abcam, 1:100) staining (10). 
For the latter two stainings positive controls are provided (images adjusted from (10).
Figure 3
(A) Family tree and C-terminal sequence of AIP 
showing amino acids from codon 327 and (B) 
nucleotides from c.981 based on NM_003977 
coding cDNA. The stop codon TGA (*) is mutated 
to CGA, which is coding for arginine (R). No stop 
codons are present in the rest of the RNA. 
Germline (C) and tumor (D) DNA sequence of the 
proband, showing reduced height for ‘T’ (normal 
sequence) allele. The lack of complete absence of 
the T allele corresponds to the pathological 
report suggesting some normal tissue in the 
sample.
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disease causing gigantism not just due to the high levels 
of GH but also due to the hypogonadism-induced growth 
causing eunuchoid proportions: his span was 16 cm larger 
than height, although the scoliosis and the shorter leg on 
one side might have confounded these measurements.
The variant identified in this patient is unusual as it 
disrupts the stop codon and replaces it with an arginine. 
There is no stop codon in the 3′UTR sequence of the cDNA 
(Fig.  3). This change is predicted to cause a lengthened 
protein, which might be misfolded and therefore rapidly 
degraded (3). Stop loss mutations are generally considered 
damaging (4). Although the tumor sample contained 
some normal tissue, the presence of loss of heterozygosity 
supports the pathogenicity of this variant. AIP staining is 
known to be unreliable for distinguishing AIP mutation-
positive tumors from negative ones (5, 6).
It was quite unexpected that the patient’s father and 
the sample from paternal aunt did not carry the mutation 
despite our initial anticipation that the paternal aunt’s 
disease was also due to this AIP mutation. Phenocopies, 
microprolactinoma or acromegaly has previously been 
described in families with AIP mutations (7, 8, 9).
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